Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 1/20 | 0.45 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.45 |
| ▸ | F10 | P00742 | 14/20 | 0.45 |
| ▸ | CNR1 | P21554 | 1/20 | 0.43 |
| ▸ | CNR2 | P34972 | 1/20 | 0.43 |
| ▸ | F2 | P00734 | 6/20 | 0.43 |
| ▸ | PRSS1 | P07477 | 5/20 | 0.43 |
| ▸ | PLG | P00747 | 1/20 | 0.43 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.43 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.43 |
| ▸ | ST14 | Q9Y5Y6 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21822503 | 0.94 | ITGB3 (0.45) | ITGB3ITGA2BF10CNR1CNR2 | |
| SCHEMBL21822613 | 0.93 | F2 (0.49) | ITGB3ITGA2BF10CNR1CNR2 | |
| SCHEMBL21822193 | 0.92 | F10 (0.45) | ITGB3ITGA2BF10CNR1CNR2 | |
| SCHEMBL21822826 | 0.90 | F10 (0.45) | ITGB3ITGA2BF10CNR1CNR2 | |
| SCHEMBL25016794 | 0.90 | F10 (0.47) | ITGB3ITGA2BF10CNR1CNR2 | |
| SCHEMBL25016792 | 0.90 | F10 (0.47) | ITGB3ITGA2BF10CNR1CNR2 | |
| SCHEMBL21822341 | 0.87 | F10 (0.49) | ITGB3ITGA2BF10CNR1CNR2 | |
| SCHEMBL21822911 | 0.83 | F10 (0.56) | ITGB3ITGA2BF10F2PRSS1 | |
| SCHEMBL25015989 | 0.82 | F2 (0.50) | ITGB3ITGA2BF10F2PRSS1 | |
| SCHEMBL25017815 | 0.82 | CCR9 (0.47) | F10F2PRSS1PRSS2PRSS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230043159-A1 | MATRIPTASE 2 INHIBITORS AND USES THEREOF | DISC MEDICINE, INC. | 2023-02-09 | — | — | US | disclosed |
| EP-3860636-A1 | MATRIPTASE 2 INHIBITORS AND USES THEREOF | Disc Medicine, Inc. (US) | 2021-08-11 | — | — | EP | disclosed |
| WO-2020072580-A1 | MATRIPTASE 2 INHIBITORS AND USES THEREOF | DISC MEDICINE, INC. (US) | 2020-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230043159-A1 | MATRIPTASE 2 INHIBITORS AND USES THEREOF | MMP7, MATR3, SPINT2 | ITGB3 2374/4885ITGA2B 2429/4885F10 1548/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.